Localizing pharmaceutical advertising: The Food and Drug Administration sets a plan for 2029
The Saudi Food and Drug Authority (SFDA) has announced a comprehensive update to its mechanism for localizing pharmaceutical advertising and the promotion of medical and herbal products. This new decision aims to empower qualified Saudi nationals in the healthcare sector. The SFDA has mandated that all pharmaceutical establishments immediately localize non-supervisory positions, with a phased plan for supervisory roles to achieve 100% Saudization by the end of June 2029.
Details of the timeline for implementing the decision to localize pharmaceutical advertising
The Saudi Food and Drug Authority (SFDA) has revealed a detailed and well-considered timeline for implementing Saudization quotas at the supervisory levels within the pharmaceutical and herbal product promotion and marketing sector. According to the new mechanism, establishments must achieve a 40% Saudization rate by the end of 2027, with this cumulative rate increasing to 80% by the end of 2028, ultimately reaching full 100% Saudization by the end of June 2029.
The authority emphasized that any vacant position at the non-supervisory level must be filled immediately by a licensed Saudi pharmacist. This important regulatory decision is based on Article 10 of the Law of Pharmaceutical and Herbal Establishments and Products, which explicitly prohibits any work in the field of advertising and promoting products except by a full-time Saudi pharmacist licensed to practice by the competent authorities.
Historical background and the process of localizing the health sector in the Kingdom
This decision comes as an extension of the Kingdom of Saudi Arabia's ongoing efforts to regulate the healthcare labor market and enhance the skills of its national workforce. Since the launch of Vision 2030, the healthcare sector has received significant strategic focus to reduce reliance on expatriate labor in critical positions and provide quality job opportunities for Saudi male and female pharmacy graduates. While the Saudi Authority for Pharmacy Education and Training (SAPE) had previously issued a mechanism for Saudization in this sector in 2019, this update immediately supersedes that mechanism, introducing a more robust and transparent framework that aligns with the rapid developments in the Saudi pharmaceutical market and the growing number of qualified Saudi graduates.
The strategic importance and expected impact of the decision locally and regionally
carries for localizing pharmaceutical advertising significant economic and health implications. At the local level, it contributes to reducing unemployment rates among graduates in scientific and pharmaceutical fields, and ensures the provision of accurate and reliable pharmaceutical information to physicians and healthcare practitioners through national staff who understand the needs of the community and adhere to the highest ethical and professional standards.
At both the regional and international levels, this regulation enhances the attractiveness of the Saudi pharmaceutical market as a well-regulated investment environment that adheres to global standards. International companies operating in the Kingdom see this decision as an opportunity to build sustainable partnerships with local talent, thereby improving the quality of their marketing and scientific performance and making the Saudi experience a model for regulating the medical advertising sector in the region.
Regulatory compliance and strict penalties for violators
The Saudi Food and Drug Authority (SFDA) clarified that this decision encompasses all employees engaged in pharmaceutical promotion and information dissemination, specifically those who visit healthcare facilities across various sectors to provide drug information. The SFDA emphasized the necessity for these facilities to amend the job titles of licensed pharmacists to fully align with the titles approved by the Ministry of Human Resources and Social Development and the Saudi Commission for Health Specialties.
The authority warned that any leniency in implementing these decisions will be met with strict penalties. Unlicensed individuals performing these tasks will face penalties including imprisonment and fines, in accordance with Article 28 of the Health Professions Practice Law. Non-compliant pharmaceutical establishments will also be subject to deterrent penalties under the Pharmaceutical and Herbal Products Law. The authority affirmed that its periodic inspection tours will continue to ensure everyone's adherence to the applicable regulations.
